Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield.
Cana will produce 1.3 million units annually of VASCLOR GEST progesterone 400mg vaginal pessaries, totaling 3.9 million units, expanding its contract manufacturing customer base and capabilities in women's health and reproductive medicine.
Positive
- Three-year contract to manufacture 3.9 million VASCLOR GEST units
- Annual volume of 1.3 million progesterone pessary units under agreement
- Expansion of Cana's contract manufacturing into women's health segment
- Diversification of Cana's customer base with Verisfield partnership
- Supports growth of Cosmos Health's high-margin contract manufacturing division
Negative
- None.
News Market Reaction – COSM
In the Jun 10 session, COSM gained 2.15%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.8% during that session. Argus tracked a trough of -18.3% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has secured a three-year contract manufacturing agreement with Verisfield S.A. (“Verisfield”), a specialty pharmaceutical company focused on the development and marketing of generic and differentiated pharmaceutical products across multiple therapeutic categories.
Under the agreement, Cana will manufacture 1.3 million units annually of VASCLOR® GEST (progesterone) 400mg vaginal pessaries, or a total of 3.9 million units over the three-year period, indicated for luteal phase support and as part of assisted reproduction treatment. The product is supplied as 400mg per pessary in boxes of 15 pessaries (in PVC-PE strips).
This agreement broadens Cana's contract manufacturing customer base and expands its capabilities into women's health and reproductive medicine. Verisfield, which began operations in 2000, markets a portfolio of more than 60 pharmaceutical products across seven therapeutic categories in Greece and internationally through strategic partners.
Greg Siokas, CEO of Cosmos Health, stated: "We are delighted to welcome Verisfield as a new contract manufacturing partner for Cana. This agreement marks a further expansion of our high-margin contract manufacturing division and diversifies our order book across additional customers and therapeutic areas, including women's health. By continuing to upgrade our European GMP-certified infrastructure and capacity, we are well-positioned to keep securing new contracts and accelerate the growth of this important segment.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
